Neurology Advisor11 天
Lumryz Approval Expanded to Include Pediatric Narcolepsy
The FDA has expanded the approval of Lumryz (sodium oxybate) extended-release oral suspension to include treatment of pediatric narcolepsy.
Mena FN7 天
Narcolepsy Treatment Market To Reach USD 8,718.3 Million By 2034 With A 5.1% Of CAGR ...
Global Narcolepsy Treatment market to Grow at 5.1% CAGR ... Usage: Approved for improving wakefulness in adults with EDS due to narcolepsy or obstructive sleep apnea. Market Position: Expected ...
Verywell Health on MSN29 天
What Medications Can You Take for Narcolepsy?
Many people require a combination of treatments ... has approved it to improve wakefulness in adults with EDS associated with ...
Neuraxpharm to further grow branded business with the acquisition of two leading narcolepsy ...
Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces today that it has acquired at the end ...
Future Market Insights6 天
Narcolepsy Treatment Industry to Reach USD 8,718.3 Million by 2034, Growing at a 5.1% CAGR
The narcolepsy treatment market is set for substantial growth, with projections indicating an increase from USD 5,301.6 million in 2024 to USD 8,718.3 million by 2034, reflecting a compound annual ...
PharmiWeb14 天
Neuraxpharm to further grow branded business with…
Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces today that it has acquired at the end ...